AgingResearch.NewsJoin free

p300/cbp inhibitor

Intervention

2 papers study it3 findings

Across all fields, 3 papers: none in people yet, 2 in animals, 1 in cells

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

  • 2 independent labs in 2 countries
  • Funders: Children's Cancer Research Fund and 1 more
  • Animals1
  • Cells1

Outcomes

3

Cellular senescence

upin human cells1

1 study

  1. p300/cbp inhibitor induces cellular senescence in human cells.

    “which when reversed by P300 inhibition leads to senescence of ES cells”

    Cellsin Ewing sarcoma cells

    Pharmacological targeting of P300/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcoma

    Molecular cancer

More on Cellular senescence

Glycolysis

downin mice1

1 study

  1. p300/cbp inhibitor decreases glycolysis in mice.

    “Pharmacological inhibition of this transcriptional coactivator before the onset of cardiac aging led to a more aerobic, less glycolytic, metabolic state, improved heart contractility, and overall blunting of cardiac decline.”

    Animalsheart

    Cardiac Aging Is Promoted by Pseudohypoxia Increasing p300-Induced Glycolysis

    Circulation research

More on Glycolysis

Heart contractility

upin mice1

1 study

  1. p300/cbp inhibitor improves heart contractility in mice.

    “Pharmacological inhibition of this transcriptional coactivator before the onset of cardiac aging led to a more aerobic, less glycolytic, metabolic state, improved heart contractility, and overall blunting of cardiac decline.”

    Animalsheart

    Cardiac Aging Is Promoted by Pseudohypoxia Increasing p300-Induced Glycolysis

    Circulation research

Latest

Related